Headline News about Regeneron Pharmaceuticals
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
Topics
Economy
Exposures
Interest Rates
Via Benzinga
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
Via Benzinga
Topics
Fraud
Exposures
Legal
Via Benzinga
Via Benzinga
Via Benzinga
Via Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via Benzinga
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
Via Benzinga
Exposures
Product Safety
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
February 22, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|